Genocea Biosciences (GNCAQ) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock GNCAQ vs. VRPX, SCPS, TRVN, ARDS, SYRS, NAVB, GNCA, STAB, EVLO, and AMPEShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Trevena (TRVN), Aridis Pharmaceuticals (ARDS), Syros Pharmaceuticals (SYRS), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Evelo Biosciences (EVLO), and Ampio Pharmaceuticals (AMPE). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Virpax Pharmaceuticals Scopus BioPharma Trevena Aridis Pharmaceuticals Syros Pharmaceuticals Navidea Biopharmaceuticals Genocea Biosciences Statera Biopharma Evelo Biosciences Ampio Pharmaceuticals Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership. Which has more volatility and risk, VRPX or GNCAQ? Virpax Pharmaceuticals has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Which has better earnings & valuation, VRPX or GNCAQ? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/AGenocea BiosciencesN/AN/AN/AN/AN/A Does the media favor VRPX or GNCAQ? In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Genocea Biosciences Neutral Is VRPX or GNCAQ more profitable? Genocea Biosciences' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Genocea Biosciences N/A N/A N/A Do institutionals and insiders believe in VRPX or GNCAQ? 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryVirpax Pharmaceuticals beats Genocea Biosciences on 3 of the 5 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCAQ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart GNCAQ vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$346.10M$6.13B$10.55BDividend YieldN/AN/A5.72%4.83%P/E RatioN/AN/A85.7827.06Price / SalesN/A464.94612.92132.30Price / CashN/A22.4425.8230.35Price / BookN/A3.6212.226.58Net IncomeN/A-$133.30M$3.33B$276.84M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070VRPXVirpax Pharmaceuticals0.2135 of 5 stars$0.01+2.7%N/A-99.9%$14KN/A0.007Gap UpSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009Gap DownTRVNTrevena1.4481 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030Gap DownSYRSSyros Pharmaceuticals3.6453 of 5 stars$0.00+100.0%$1.00+249,900.0%-100.0%$11K$386K0.00120NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010High Trading VolumeGNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00flatN/AN/A$5KN/A0.0020Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/A-33.3%$4KN/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020 Related Companies and Tools Related Companies Virpax Pharmaceuticals Competitors Scopus BioPharma Competitors Trevena Competitors Aridis Pharmaceuticals Competitors Syros Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors Genocea Biosciences Competitors Statera Biopharma Competitors Evelo Biosciences Competitors Ampio Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCAQ) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
